Drugs / KAHR-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02545361 | Apr 2018 → Apr 2020 | lymphoma | Kahr Medical | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KAHR-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02545361 ↗ |
| Modality | Protein / enzyme biologic | “KAHR-102 is a dual signaling protein (DSP).” NCT02545361 ↗ |
| Route | Subcutaneous | “KAHR-102 will be administrated subcutaneously.” NCT02545361 ↗ |